Barclays Issues Positive Forecast for West Pharmaceutical Services (NYSE:WST) Stock Price

Key Points

• Barclays raised its price target for West Pharmaceutical Services from $440 to $500 and maintained an “overweight” rating, implying roughly 22% upside from the reported share price.
• Analyst sentiment remains favorable: 12 analysts rate the stock Buy and two rate it Hold, producing a “Moderate Buy” consensus and an average price target of $396.17.
• West exceeded quarterly expectations, reporting $2.66 in EPS and $874.5 million in revenue, with sales up 8.7% year over year; high-value product sales increased 19.7% and supported the company’s growth outlook.

West Pharmaceutical Services (NYSE:WST - Get Free Report) had its price objective increased by analysts at Barclays from $440.00 to $500.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical instruments supplier's stock. Barclays's price target suggests a potential upside of 22.31% from the stock's current price.

Several other equities research analysts have also recently commented on the company. Evercore reissued an "outperform" rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Citigroup upped their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Weiss Ratings upgraded shares of West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 7th. Wall Street Zen lowered shares of West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research note on Saturday, October 24th. Finally, BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday, July 13th. They set an "outperform" rating and a $447.00 target price for the company. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $396.17.

West Pharmaceutical Services Price Performance

NYSE:WST traded down $7.89 during mid-day trading on Friday, reaching $408.78. 252,677 shares of the company were exchanged, compared to its average volume of 805,160. West Pharmaceutical Services has a 12 month low of $223.83 and a 12 month high of $438.27. The company has a fifty day moving average of $366.60 and a 200 day moving average of $312.50. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $28.77 billion, a PE ratio of 52.51, a PEG ratio of 2.83 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $874.50 million during the quarter, compared to the consensus estimate of $827.12 million. During the same period in the previous year, the firm posted $1.96 earnings per share. The company's revenue was up 8.7% on a year-over-year basis. On average, research analysts anticipate that West Pharmaceutical Services will post 8.92 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Annette Favorite sold 2,524 shares of the firm's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total value of $921,260.00. Following the completion of the transaction, the vice president owned 21,818 shares in the company, valued at $7,963,570. This trade represents a 10.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 15,659 shares of company stock worth $5,443,749. Insiders own 0.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of West Pharmaceutical Services in the second quarter valued at about $2,387,990,000. State Street Corp increased its position in West Pharmaceutical Services by 1.7% during the second quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier's stock worth $1,202,183,000 after acquiring an additional 54,920 shares during the period. Bank of New York Mellon Corp bought a new position in West Pharmaceutical Services during the second quarter worth about $733,733,000. Generation Investment Management LLP acquired a new stake in West Pharmaceutical Services in the 2nd quarter worth about $728,168,000. Finally, Amundi raised its stake in West Pharmaceutical Services by 85.4% in the 1st quarter. Amundi now owns 644,065 shares of the medical instruments supplier's stock worth $161,428,000 after purchasing an additional 296,639 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, ahead of the $2.18-$2.20 analyst consensus, while revenue reached $874.5 million versus expectations of approximately $827 million. Revenue increased 8.7% year over year, and earnings rose from $1.96 per share in the prior-year quarter. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised: Management now expects 2026 net sales of $3.41 billion to $3.42 billion, up from $3.345 billion to $3.380 billion previously. Adjusted diluted EPS guidance increased to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: High-value products led growth: High-Value Product Components sales rose 19.7% and represented 53% of quarterly sales. The mix shift supported margin expansion and reinforced investor confidence in demand for West’s pharmaceutical packaging and delivery components. West Pharma Q3 Earnings Rise on HVP Strength

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.